New Biomarkers Could Expose Cat Kidney Disease Earlier
A study published November 6, 2026, offers a sharper way to think about chronic kidney disease in cats: not as one uniform failure revealed by one late number, but as several biological patterns that may leave different protein traces in urine. Researchers found more than 2,200 urinary proteins, identified MMP-7 as a promising early-stage signal, and detected three protein-profile groups among cats with advanced disease. This is important science, but it is not yet a clinic-ready test. The real breakthrough is a map of candidates—and a framework for discovering which cats may be traveling different paths under the same diagnosis.
What the new feline kidney study actually found
The Journal of Proteome Research paper analyzed urine from 30 healthy cats and 34 cats diagnosed with chronic kidney disease, or CKD. The work came from Jessica Quimby’s feline CKD research program at The Ohio State University. Using mass spectrometry, the team cataloged 2,219 proteins and compared how individual proteins and broader protein patterns changed across disease states.
One candidate stood out: matrix metalloproteinase-7, or MMP-7, was elevated in cats with early-stage CKD compared with healthy controls. The researchers also grouped proteins by the way their abundance rose or fell across disease. That larger pattern divided late-stage cases into three clusters: one associated with apparently stable disease, one including younger males with advanced proteinuric disease, and one suggesting a less stable late-stage state.
The American Chemical Society’s November 9 summary calls these findings promising biomarkers. “Promising” is the load-bearing word. The study discovered signals worth testing; it did not establish a commercial diagnostic, a universal cutoff, or proof that acting on the signals improves outcomes.
Why urine can reveal what blood averages away
Kidneys filter blood, reclaim useful molecules, regulate water and electrolytes, and send waste into urine. Blood tests such as creatinine and symmetric dimethylarginine, or SDMA, can reveal declining filtration. Urine concentration and urinary protein also add important information. Yet these measurements often describe consequences shared by many injuries. They can say the system is struggling without identifying the mechanism that pushed it there.
Proteomics asks a different question: which proteins are present, and how does the whole pattern change? Some proteins may reflect damaged tubules, altered filtration barriers, inflammation, remodeling, or a systemic response to disease. A single molecule can be a useful alarm. A profile can be more like a chord: several notes whose relationship may distinguish one biological process from another.
That distinction matters because CKD is an umbrella term. Two cats can occupy the same clinical stage while differing in cause, rate of progression, protein loss, age, or response to treatment. A panel that sorts those hidden differences could eventually support earlier detection or more precise subtyping. It might also fail outside the original sample. Discovery is the beginning of a diagnostic argument, not its verdict.
MMP-7 is a candidate, not a crystal ball
MMP-7 is an enzyme involved in remodeling the material around cells. Its elevation can accompany tissue injury and repair in several organs and species, which makes it biologically plausible but not automatically kidney-specific. A marker is useful only if it separates the condition of interest from healthy aging, dehydration, acute illness, medication effects, and other diseases that may shift the same signal.
The study’s 64 cats are enough to reveal patterns, but too few to define every breed, age group, comorbidity, diet, or clinical setting. The cohorts also need independent replication. A robust next phase would test blinded samples from multiple hospitals, establish reference ranges, compare the assay with existing staging tools, and measure sensitivity, specificity, and performance over time.
A second 2026 study in Scientific Reports used serum proteomics in independent discovery and validation cohorts and confirmed several different candidate proteins. The overlap is not perfect, and that is useful rather than embarrassing. Blood and urine sample different biological compartments. Multiple research programs finding distinct but testable signals is what an emerging field looks like before it settles on a practical panel.
The three gates between discovery and a real test
Biomarker headlines become easier to judge when you pass them through three gates. First is analytical validity: can a laboratory measure the protein accurately, repeatedly, and affordably in ordinary samples? Mass spectrometry is powerful for discovery, but a clinical assay usually needs a simpler standardized format.
Second is clinical validity: does the result reliably distinguish early CKD or a meaningful subtype in a broad population? This requires larger, diverse cohorts and comparisons with the best current methods. Researchers must decide whether the marker adds information beyond creatinine, SDMA, urine specific gravity, protein measurements, blood pressure, imaging, history, and physical examination.
Third is clinical utility: does knowing the result change care in a way that helps cats? Earlier information is valuable only when it leads to a decision—closer monitoring, a justified intervention, or avoidance of an ineffective one. A test can be statistically impressive yet clinically irrelevant if it does not alter management or outcomes.
That framework echoes the lesson of the newly described tiger cat Leopardus tilcayo: finer classification can expose differences that a broad label conceals. But a more detailed map creates obligations. Scientists must show that the boundaries are stable, useful, and connected to the world beyond the dataset.
What cat guardians should—and should not—take from this
This research should not prompt anyone to diagnose a cat from a headline, delay routine veterinary care while waiting for a future assay, or assume a normal-looking cat has no kidney disease. It is also not a reason to request MMP-7 testing from a clinic today. The study concerns candidate biomarkers under research conditions, not a standard consumer test.
The reasonable takeaway is more hopeful and less cinematic. Urine may contain a richer record of feline kidney disease than current routines can fully read. If researchers can validate that record, clinicians may eventually detect some cases earlier and distinguish disease patterns that now share one name. The work also demonstrates why modern science increasingly studies systems rather than hunting for one magic molecule.
That systems view is familiar from the fire amoeba study: survival at an extreme temperature could not be explained by one trick, but by coordinated protection, repair, and ecology. Likewise, a chronic disease is rarely one broken switch. Protein profiles can reveal relationships among processes that an isolated measurement misses.
A better future test would be humble
The most trustworthy feline CKD assay would not claim omniscience. It would state what population it was validated in, how often it misses disease, how often it raises false alarms, whether age and other illnesses distort the result, and what decision it is meant to support. Its power would come from narrowing uncertainty, not pretending uncertainty has vanished.
This study deserves attention because it replaces a flat category with a structured problem: early signal, disease subtype, mechanism, and progression may be separable questions. MMP-7 is one lead. The larger urinary proteome may be the more important discovery. The next work is slower—replication, standardization, prospective follow-up, and evidence that better classification produces better care.
Your turn
If an earlier feline kidney-disease test becomes reliable, what should matter most before clinics adopt it—accuracy, cost, ease of sampling, or evidence that it improves cats’ outcomes?
For cat-coded design without medical promises, explore the Cat-Coded collection and bring your answer to the Claw & Riot Salon.




Comments